Success Story: Chinese Senior Scientist Earns EB1A Approval for Advancing Organic Chemistry and Molecular Design

Client’s Testimonial:

“Even though it took a little bit longer (I believe I need to ask more questions about the process), it was still a good experience for me to work with the team and attorney. Thanks to all of you!”

On November 19^th, 2025, we received another EB1A (Alien of Extraordinary Ability) approval for a Senior Scientist in the field of Organic Chemistry (Approval Notice).

General Field: Organic Chemistry

Position at the Time of Case Filing: Senior Scientist

Country of Origin: China

State of Residence at the Time of Filing: Massachusetts

Approval Notice Date: November 19^th, 2025

Processing Time: 4 months, 1 day (Premium Processing Upgrade Requested)

Case Summary:

We are pleased to share the EB1A approval of a senior scientist from China whose work advances organic chemistry through research in small molecules, peptides, oligonucleotides, and nanocatalyst-supported chemical transformations. At the time of filing, he was conducting research on controlled nanocrystal synthesis, biomolecular detection materials, and molecular designs relevant to neurodegenerative and oncological applications. With a strong publication record, hundreds of citations, and significant peer review service, he presented a compelling case for EB1A approval.

Extraordinary Research Contributions

The client’s research includes developing nanocatalyst-supported systems for selective organic redox reactions, creating nanomaterials for biomolecular detection, engineering glutathione-mimic peptides and prodrugs used in Alzheimer’s disease studies, and designing reactive oxygen species–activated scaffolds for cancer-related applications. His findings have improved catalyst efficiency and selectivity, enabled more sensitive detection of disease-related biomolecules, and informed studies on neurodegeneration and targeted cancer therapy. These contributions have been widely applied and cited by researchers around the world, demonstrating their significance within organic chemistry.

Academic Record and Recognition

The client has authored 15 peer-reviewed journal articles, 3 abstracts, and 1 book chapter, earning 591 independent citations. His work appears in leading journals such as ACS Nano, Journal of Materials Chemistry A, and Free Radical Biology and Medicine, with several papers ranking among the most highly cited in chemistry. He has completed at least 20 peer reviews for respected journals and contributed to federally supported research funded by the National Institutes of Health, Department of Defense, and National Science Foundation, further underscoring his professional standing.

Expert Endorsements

Independent experts highlighted the national value and scientific influence of his contributions.

One recommender wrote:

“Given the importance of these contributions, I strongly advocate for the continuation of [client]’s research efforts in the United States, where they stand to benefit patients and medical systems alike.”

This endorsement affirms the originality of his work and the lasting impact of his research.

EB1A Approval and Outlook

The I-140 EB1A petition was filed on July 18, 2025, upgraded to premium processing, and approved on November 19, 2025. With NAILG’s support, the client demonstrated extraordinary ability through his publication record, citation influence, and contributions of major significance. He now continues his research in the United States, advancing catalytic methodologies, biomolecular detection systems, and molecular design strategies that strengthen national leadership in organic chemistry.

--------------------------------------------

North America Immigration Law Group (Chen Immigration Law Associates) is a U.S. immigration law firm dedicated to representing corporations, research institutions, and individuals from all 50 U.S. states regarding I-140 immigration petitions. We specialize in employment-based immigration petition and have a proven record of high success rate for the categories of: EB2-NIW (National Interest Waiver), EB1-A (Alien of Extraordinary Ability), EB1-B (Outstanding Researcher/Professor) and O-1 (Alien of Extraordinary Ability).

Our Ten Thousand I-140 Approvals Provide Unprecedented Insight into the USCIS Adjudication Trend

With more than 58,000 EB-1A, EB-1B, EB-2 NIW and O-1 cases approved, we have first hand information on the manner in which the USCIS adjudicate I-140 cases. As the USCIS has constantly changed its adjudication standards for the EB-1A, EB-1B and EB-2 NIW categories, our firm's huge database of successful cases gives you unprecedented insight to USCIS adjudication trends. We carefully analyze the data for all of our cases and apply the results of our analyses toward giving our clients up-to-date advice and adapting our strategies such that we remain on par with the ever-shifting landscape of immigration law in the U.S. With us, you will always have access to important updates, strategies, and information so that you can make the most informed decisions about your case.

We Have Helped Tens of Thousands of Clients with Credentials and Backgrounds Similar to Yours

With our exceedingly large number of successful petitions, no matter what credentials you have, no matter your background and field of expertise, no matter your visa status or nationality, chances are we have helped hundreds or even thousands of clients just like you. Our clients are usually impressed with how well we understand their research and work. Our insight and understanding stems from the fact that we have handled many cases with elements similar to yours already, and this helps us devise the best strategies for each individual petition.

Vast Majority of Clients Came to Us Because of Referrals

For years, our firm has attracted new clients based solely on word of mouth, recommendations, and the positive collaboration experiences shared with them by their friends and family. We take pride in our reputation and work hard to ensure that we provide a green card application experience that our clients are happy to share with their friends and colleagues. That is how our cumulative total of approved cases grew from 600 in 2013 to over 58,000 in 2025.